MCID: NPH010
MIFTS: 45

Nephrosclerosis

Categories: Cardiovascular diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Nephrosclerosis

MalaCards integrated aliases for Nephrosclerosis:

Name: Nephrosclerosis 12 77 54 56 45 15 17 74
Renal Sclerosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11664
ICD9CM 36 587
MeSH 45 D009400
SNOMED-CT 69 32916005
ICD10 34 I12 N26.9
UMLS 74 C0027719

Summaries for Nephrosclerosis

MalaCards based summary : Nephrosclerosis, also known as renal sclerosis, is related to malignant hypertension and renal hypertension. An important gene associated with Nephrosclerosis is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are p70S6K Signaling and Dilated cardiomyopathy (DCM). The drugs Prednisone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, pituitary and bone, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 77 Hypertensive kidney disease is a medical condition referring to damage to the kidney due to chronic high... more...

Related Diseases for Nephrosclerosis

Diseases related to Nephrosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Related Disease Score Top Affiliating Genes
1 malignant hypertension 30.5 ACE ADAMTS13 AGTR1
2 renal hypertension 30.2 ACE AGTR1
3 hypertensive heart disease 30.1 ACE AGTR1 NR3C2
4 renovascular hypertension 30.1 ACE AGTR1
5 glomerulonephritis 29.9 CCL2 NPHS1 NPHS2 TGFB1
6 heart disease 29.7 ACE ADRB1 AGTR1 MTHFR
7 microvascular complications of diabetes 3 29.7 ACE AGTR1 NPHS1
8 coronary heart disease 1 29.6 ACE ADRB1 MTHFR
9 hypertension, essential 29.6 ACE ADRB1 AGTR1 NR3C2
10 end stage renal failure 29.1 ACE AGTR1 NPHS1 NPHS2 TGFB1
11 kidney disease 29.0 ACE AGTR1 CCL2 NPHS1 NPHS2 NR3C2
12 chronic kidney failure 28.9 ACE AGTR1 MTHFR NPHS1 NPHS2 TGFB1
13 iga glomerulonephritis 28.8 ACE AGTR1 CCL2 NPHS1 NPHS2 TGFB1
14 renal artery disease 10.4 ACE AGTR1
15 familial vesicoureteral reflux 10.4 ACE TGFB1
16 hypertensive nephropathy 10.3 ACE AGTR1
17 diastolic heart failure 10.3 ACE AGTR1
18 diabetic foot ulcers 10.3 CCL2 TGFB1
19 ascending cholangitis 10.3 CCL2 TGFB1
20 arteritic anterior ischemic optic neuropathy 10.3 ACE MTHFR
21 renal tubular dysgenesis 10.2 ACE AGTR1
22 peyronie's disease 10.2 CCL2 TGFB1
23 nonspecific interstitial pneumonia 10.2 CCL2 TGFB1
24 posterior urethral valves 10.2 ACE AGTR1 TGFB1
25 evans' syndrome 10.2 ADAMTS13 TGFB1
26 fibromuscular dysplasia 10.2 ACE AGTR1 TGFB1
27 cerebral atherosclerosis 10.2 ACE MTHFR
28 tuberculous meningitis 10.2 CCL2 TGFB1
29 hemolytic-uremic syndrome 10.2
30 idiopathic edema 10.2 ACE NR3C2
31 arteries, anomalies of 10.2 ACE AGTR1 CCL2
32 silicosis 10.2 ACE CCL2 TGFB1
33 retinal artery occlusion 10.2 ACE MTHFR
34 pyelonephritis 10.1
35 polyarteritis nodosa 10.1
36 meningococcal infection 10.1 ADRB1 AGTR1
37 retinal vascular occlusion 10.1 CCL2 MTHFR
38 crescentic glomerulonephritis 10.1 CCL2 NPHS2 SYNPO
39 catastrophic antiphospholipid syndrome 10.1 ADAMTS13 MTHFR
40 anuria 10.1 ACE AGTR1 NR3C2
41 grange syndrome 10.1 CCL2 MTHFR
42 ischemic heart disease 10.1 ACE AGTR1 MTHFR
43 ischemic optic neuropathy 10.1 ACE AGTR1 MTHFR
44 nonarteritic anterior ischemic optic neuropathy 10.1 ACE AGTR1 MTHFR
45 arteriosclerosis 10.1
46 ischemia 10.1
47 uremia 10.1
48 heart valve disease 10.1 ACE NR3C2 TGFB1
49 acute mountain sickness 10.1 ACE AGTR1
50 cerebrovascular disease 10.1 ACE AGTR1 MTHFR

Comorbidity relations with Nephrosclerosis via Phenotypic Disease Network (PDN):


Acute Cystitis Acute Kidney Failure
Chronic Kidney Failure Deficiency Anemia
Heart Disease Hydronephrosis
Hypertension, Essential Ischemic Heart Disease
Kidney Disease Nephrolithiasis, X-Linked Recessive, with Renal Failure

Graphical network of the top 20 diseases related to Nephrosclerosis:



Diseases related to Nephrosclerosis

Symptoms & Phenotypes for Nephrosclerosis

MGI Mouse Phenotypes related to Nephrosclerosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.87 ACE ADRB1 AGTR1 BMP5 NPHS2 NR3C2
2 growth/size/body region MP:0005378 9.86 ACE ADRB1 AGTR1 BMP5 MTHFR NPHS2
3 homeostasis/metabolism MP:0005376 9.85 ACE ADAMTS13 ADRB1 AGTR1 BMP5 MTHFR
4 mortality/aging MP:0010768 9.65 ACE ADAMTS13 ADRB1 AGTR1 BMP5 MTHFR
5 renal/urinary system MP:0005367 9.23 ACE AGTR1 BMP5 NPHS1 NPHS2 NR3C2

Drugs & Therapeutics for Nephrosclerosis

Drugs for Nephrosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 5284616 6436030
4
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8 Anti-Inflammatory Agents Phase 4
9 Antineoplastic Agents, Hormonal Phase 4
10 Antibiotics, Antitubercular Phase 4
11 Hormone Antagonists Phase 4
12 Antirheumatic Agents Phase 4
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
14 Dermatologic Agents Phase 4
15 Antifungal Agents Phase 4
16 Antitubercular Agents Phase 4
17 Immunosuppressive Agents Phase 4
18 Anti-Bacterial Agents Phase 4
19 glucocorticoids Phase 4
20 Calcineurin Inhibitors Phase 4
21 Cyclosporins Phase 4
22 Hormones Phase 4
23 Anti-Infective Agents Phase 4
24 Immunologic Factors Phase 4
25 Antihypertensive Agents Phase 4,Phase 2,Phase 3
26 Angiotensin Receptor Antagonists Phase 4
27 Giapreza Phase 4
28 Angiotensinogen Phase 4
29 Angiotensin II Type 1 Receptor Blockers Phase 4
30
Epoprostenol Approved Phase 2, Phase 3 35121-78-9, 61849-14-7 5282411 5280427
31 Tezosentan Investigational Phase 2, Phase 3 180384-57-0
32 Beraprost Investigational Phase 2, Phase 3 88430-50-6
33 Vasodilator Agents Phase 2, Phase 3
34 Platelet Aggregation Inhibitors Phase 2, Phase 3
35
Lovastatin Approved, Investigational 75330-75-5 53232
36
Pravastatin Approved 81093-37-0 54687
37
Simvastatin Approved 79902-63-9 54454
38
Atorvastatin Approved 134523-00-5 60823
39
Calcium Approved, Nutraceutical 7440-70-2 271
40 Antimetabolites
41 Dihydromevinolin
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors
43 L 647318
44 Calcium, Dietary
45 Anticholesteremic Agents
46 Rosuvastatin Calcium 147098-20-2
47 Lipid Regulating Agents
48 Hypolipidemic Agents
49 Epoetin alfa 113427-24-0
50 Hematinics

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus Completed NCT00371826 Phase 4 Everolimus (RAD001);Cyclosporine (Calcineurin Inhibitor (CNI));Methylprednisone/prednisone;Mycophenolate sodium (MPA)
2 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
3 TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT01090037 Phase 2, Phase 3 TRK-100STP high dose;TRK-100STP low dose;Placebo
4 TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT02480751 Phase 2 Beraprost;Placebo
5 Renal NCE-MRI in Healthy Volunteers Completed NCT02618460 Not Applicable
6 High Potency Statins and Acute Kidney Injury Completed NCT02518516 Rosuvastatin (≥10 mg);Atorvastatin (≥20 mg);Simvastatin (≥40 mg);Fluvastatin;Pravastatin;Lovastatin;Atorvastatin (<20mg);Simvastatin (<40 mg)
7 An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant Completed NCT02538107 Methoxy-polyethyleneglycol epoetin beta
8 The Validity of the Quick Renal MRI in Pediatric Kidney Disease Recruiting NCT03959163 Not Applicable

Search NIH Clinical Center for Nephrosclerosis

Cochrane evidence based reviews: nephrosclerosis

Genetic Tests for Nephrosclerosis

Anatomical Context for Nephrosclerosis

MalaCards organs/tissues related to Nephrosclerosis:

42
Kidney, Pituitary, Bone, Pancreas, Smooth Muscle, Spleen, Cortex

Publications for Nephrosclerosis

Articles related to Nephrosclerosis:

(show top 50) (show all 293)
# Title Authors Year
1
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis. ( 30809002 )
2019
2
Gene Expression Studies and Targeted Metabolomics Reveal Disturbed Serine, Methionine, and Tyrosine Metabolism in Early Hypertensive Nephrosclerosis. ( 30775629 )
2019
3
Amplified Association Between Blood Pressure and Albuminuria in Overweight Patients With Biopsy-Proven Hypertensive Nephrosclerosis. ( 30689693 )
2019
4
Larger nephron size, low nephron number, and nephrosclerosis on biopsy as predictors of kidney function after donating a kidney. ( 30629312 )
2019
5
Volume Ratio of Glomerular Tufts to Bowman Capsules and Renal Outcomes in Nephrosclerosis. ( 30358804 )
2018
6
Impact of high mortality in incident dialysis patients due to hypertensive nephrosclerosis: a multicenter prospective cohort study in Aichi, Japan. ( 29882111 )
2018
7
Investigation into the underlying molecular mechanisms of hypertensive nephrosclerosis using bioinformatics analyses. ( 29328390 )
2018
8
Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis. ( 29127556 )
2018
9
Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. ( 29788462 )
2018
10
Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. ( 27784849 )
2017
11
Curcumin ameliorates nephrosclerosis via suppression of histone acetylation independent of hypertension. ( 27190365 )
2016
12
Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study. ( 27066888 )
2016
13
Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. ( 26857648 )
2016
14
Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map. ( 26839894 )
2016
15
Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis. ( 26809068 )
2016
16
Malignant nephrosclerosis in a patient with familial Mediterranean fever. ( 26466703 )
2015
17
The Renal Protective Effect of Jiangya Tongluo Formula, through Regulation of Adrenomedullin and Angiotensin II, in Rats with Hypertensive Nephrosclerosis. ( 26557147 )
2015
18
Nephrosclerosis: a term in quest of a disease. ( 25871843 )
2015
19
Patients with biopsy-proven nephrosclerosis and moderately impaired renal function have a higher risk for cardiovascular disease: 15 years' experience in a single, kidney disease center. ( 25838316 )
2015
20
Glomerular Density in Biopsy-Proven Hypertensive Nephrosclerosis. ( 25631380 )
2015
21
Nephrosclerosis: update on a centenarian. ( 25488894 )
2015
22
A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. ( 25233856 )
2014
23
Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model. ( 24958497 )
2014
24
Hypertension, glomerular hypertrophy and nephrosclerosis: the effect of race. ( 24327566 )
2014
25
Subclinical nephrosclerosis is linked to left ventricular hypertrophy independent of classical atherogenic factors. ( 24305517 )
2014
26
Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. ( 24136919 )
2014
27
Prevalence and risk factor analysis of nephrosclerosis and ischemic nephropathy in the Japanese general population. ( 23832327 )
2014
28
Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat. ( 24066937 )
2014
29
Castleman's disease accompanied by hypolipidemic cerebral hemorrhage and nephrosclerosis. ( 23857095 )
2013
30
Effect of intensive blood pressure control on cardiovascular remodeling in hypertensive patients with nephrosclerosis. ( 24102027 )
2013
31
Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine. ( 23902971 )
2013
32
Hypertensive nephrosclerosis: not enough of a good thing? ( 23283991 )
2013
33
Serum potassium predicts time to blood pressure response among African Americans with hypertensive nephrosclerosis. ( 23151750 )
2013
34
Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis. ( 23135868 )
2013
35
Need for education on the differential diagnosis between chronic glomerulonephritis and nephrosclerosis, and treatment of both conditions to reduce the number of patients requiring hemodialysis in Wakayama. ( 22821095 )
2012
36
Arteriolar vascular smooth muscle cell differentiation in benign nephrosclerosis. ( 22319217 )
2012
37
Association of hypoalbuminemia with severe anemia in patients with diabetic nephrosclerosis. ( 22236281 )
2012
38
Hypertensive nephrosclerosis in Kenya. ( 22179094 )
2011
39
Senile nephrosclerosis--does it explain the decline in glomerular filtration rate with aging? ( 21832860 )
2011
40
Nephrosclerosis and carotid atherosclerosis: lessons from kidney donor histology. ( 21777346 )
2011
41
Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis. ( 21346373 )
2011
42
The role of bone morphogenetic protein-5 (BMP-5) in human nephrosclerosis. ( 21319131 )
2011
43
ADAMTS13--marker of contractile phenotype of arterial smooth muscle cells lost in benign nephrosclerosis. ( 20923926 )
2011
44
Involvement of connective tissue growth factor in human and experimental hypertensive nephrosclerosis. ( 20689330 )
2011
45
Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis. ( 21080950 )
2010
46
Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort. ( 20801567 )
2010
47
Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. ( 20651163 )
2010
48
Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. ( 20484896 )
2010
49
The association between age and nephrosclerosis on renal biopsy among healthy adults. ( 20439574 )
2010
50
Human nephrosclerosis triggers a hypoxia-related glomerulopathy. ( 20019191 )
2010

Variations for Nephrosclerosis

Expression for Nephrosclerosis

Search GEO for disease gene expression data for Nephrosclerosis.

Pathways for Nephrosclerosis

GO Terms for Nephrosclerosis

Cellular components related to Nephrosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 slit diaphragm GO:0036057 8.62 NPHS1 NPHS2

Biological processes related to Nephrosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase B signaling GO:0043491 9.46 CCL2 TGFB1
2 excretion GO:0007588 9.43 NPHS1 NPHS2
3 lipopolysaccharide-mediated signaling pathway GO:0031663 9.4 CCL2 TGFB1
4 regulation of vasoconstriction GO:0019229 9.37 ACE AGTR1
5 positive regulation of cellular protein metabolic process GO:0032270 9.32 AGTR1 TGFB1
6 peptide catabolic process GO:0043171 9.26 ACE ADAMTS13
7 regulation of blood vessel diameter GO:0097746 9.16 ACE AGTR1
8 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 ACE AGTR1
9 mononuclear cell proliferation GO:0032943 8.62 ACE TGFB1

Molecular functions related to Nephrosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.13 BMP5 CCL2 TGFB1
2 bradykinin receptor binding GO:0031711 8.62 ACE AGTR1

Sources for Nephrosclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....